04:17 AM EDT, 06/30/2025 (MT Newswires) -- Argenx (ARGX) said Monday it plans to advance the clinical development of ARGX-119 to a registrational study in patients with congenital myasthenic syndromes.

The treatment showed a favorable safety and tolerability profile in a phase 1b study, which was its primary endpoint, the company said.

Congenital myasthenic syndromes are a rare group of congenital neuromuscular disorders.